WINS2 Inhibitors
WINS2 inhibitors represent a category of chemical agents that have been synthesized to engage with a specific molecular entity known as WINS2. The function of WINS2 within biological systems is diverse, and the mechanisms by which these inhibitors interfere with its activity are rooted in intricate biochemical interactions. The discovery of such inhibitors often starts with a comprehensive screening process to identify molecules that demonstrate a high affinity for binding to WINS2. The specificity of this binding is of paramount importance, as it ensures the precision of the inhibitor's action on its intended target, while minimizing interactions with other molecules.
The chemical composition of WINS2 inhibitors is varied, reflecting the myriad of approaches employed in their development. These compounds may be small, organically-based molecules or larger biological entities such as peptides. Their creation is frequently guided by sophisticated techniques like structure-based design, which necessitates a deep understanding of the molecular architecture of WINS2. The inhibitors are crafted to mimic the natural ligands of the target, thereby obstructing the normal activity of WINS2. The strength and type of the interaction between the inhibitor and WINS2 can range from weak and reversible to strong and permanent, and involve different types of non-covalent bonding such as ionic interactions and hydrophobic contacts. In the iterative process of refining these inhibitors, chemists and researchers analyze the relationship between the molecular structure of the compounds and their inhibitory potency, a concept known as structure-activity relationship (SAR). Through numerous cycles of design, synthesis, and evaluation, these inhibitors are continually optimized, which contributes to a broader understanding of their chemical properties and the role they play in modulating the activity of WINS2.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
This is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which are involved in various signaling pathways. By inhibiting PI3K, Wortmannin would indirectly lead to the inhibition of WINS2 if WINS2 is downstream of PI3K signaling or dependent on PI3K activation for its functional activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor, similar to Wortmannin. By blocking PI3K, LY294002 can reduce the activity of downstream molecules in the PI3K/Akt pathway, potentially resulting in the inhibition of WINS2 if it is functionally associated with this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, which plays a key role in the PI3K/AKT/mTOR pathway. The inhibition of mTOR can lead to decreased protein synthesis and cell proliferation, which could indirectly inhibit WINS2 if its activity is linked to mTOR signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor, which prevents the activation of the downstream effector, ERK. Inhibition of this MAPK pathway can result in the functional inhibition of WINS2, assuming WINS2 is involved in this signaling cascade. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. By inhibiting p38 MAPK, the chemical may decrease the activation of transcription factors and other proteins that are responsive to stress stimuli, potentially inhibiting WINS2 if it is involved in stress response pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is implicated in inflammation and apoptosis. Inhibiting JNK can disrupt these processes and could inhibit WINS2 if it plays a role in the JNK pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of both MEK1 and MEK2. As with PD98059, it can inhibit the MAPK/ERK pathway, potentially leading to decreased function of WINS2 if it is involved in ERK signaling. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor. By disrupting the degradation of ubiquitinated proteins, it can affect multiple signaling pathways, which could result in the inhibition of WINS2 if it is regulated by proteasomal degradation. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. Src kinases participate in various signaling pathways, including cell growth and differentiation. Inhibiting Src kinases could decrease WINS2 activity if WINS2 is involved in Src-mediated signaling. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib inhibits Bcr-Abl tyrosine kinase, and by doing so, it affects the downstream signaling pathways involved in cell growth and survival. This inhibition could potentially decrease the activity of WINS2 if it is associated with these pathways. | ||||||